Early Interception of Inflammatory-mediated Type 2 Diabetes

  • INTERCEPT-T2D aims to identify high-risk Type 2 Diabetes patients by investigating the role of inflammation in the development of complications.
arrow bottom T2B blanc

Inflammatory markers should be used in diabetes medical care to refine T2D associated phenotypes

The overall concept of INTERCEPT-T2D is to establish whether an inflammatory-mediated profile contributes to the onset of Type 2 Diabetes (T2D) complications, thus enabling the identification of patients most at risk of complications and the design of personalized prevention measures.

picto-stratify intercept t2D

01. Stratify

Stratify T2D trajectories from early stages to long-term complications and establish the Inflammatory-mediated T2D subtype,


02. Identify

Identify immune biomarkers characteristic of inflammatory-mediated T2D: emergence of a T2D Inflammatory Score


03. Verify

Verify the causal role of inflammation in the transition to diabetes related complication, and elucidate the molecular mechanisms underlying this inflammatory-mediated progression in T2D


04. Evaluate

Evaluate the clinical impact of our interceptive approach in a phase 2 proof-of-concept trial evaluating the efficacy of a novel anti-inflammatory therapy targeting the NLRP3 inflammasome, on glyceamiccontrol and chronic complications,


05. Propose

Propose stratified strategies and guidance to healthcare professionals and patients to interceptthis inflammatory transition and to concentrate public health care resources on patients with the highest risk of T2D complications.

Specific objectives

To investigate the potential of preventing the transition to organ complications, INTERCEPT-T2D will conduct a phase II clinical trial involving an anti-inflammatory therapy targeting NLRP3 Inflammasome activity in T2D patients.

The project
in numbers








EU contribution

Latest news

First patient enrolled in the project’s clinical study

First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile

Presentation of INTERCEPT-T2D’s Coordinator in the FFD newsletter (in french)

*Article in French* Read an article made by our partner  “the Federation Française des diabétiques” about the project’s coordinator Nicolas Venteclef and the project INTERCEPT-T2D in their newsletter

2nd consortium meeting 6&7 December Basel

The consortium met again in Basel on the 6&7 of December to review the progress and accomplishments of the year 2023.

A team of European partners